comScore
Active Stocks
Tue Oct 03 2023 10:52:59
  1. Tata Steel share price
  2. 127.55 -1.12%
  1. Tata Motors share price
  2. 622.25 -1.29%
  1. HDFC Bank share price
  2. 1,511.5 -0.99%
  1. Power Grid Corporation Of India share price
  2. 198.3 -0.78%
  1. NTPC share price
  2. 244.85 -0.33%
Business News/ Markets / Stock Markets/  Zydus Lifesciences Q4 results: Net profit falls 25% YoY to 296.6 crore; declares dividend of 6
Back

Zydus Lifesciences Q4 results: Net profit falls 25% YoY to ₹296.6 crore; declares dividend of ₹6

The company’s board of directors also recommended a final dividend of ₹6 per equity share of Re 1 each, subject to approval of the shareholders. The record date for dividend has been fixed at July 28, 2023.

Zydus Lifesciences’s US formulations business registered revenues of  ₹2,252.5 crore.Premium
Zydus Lifesciences’s US formulations business registered revenues of 2,252.5 crore.

Zydus Lifesciences’s net profit for the fiscal fourth quarter ended March 2023 dropped 25.4% to 296.6 crore from 397.4 crore in the corresponding quarter of last fiscal.

The sharp decline in profit was largely due to a one-time loss of 601.3 crore, which includes impairment of goodwill relating to Sentynl Therapeutics and expenses incurred in connection with cessation of operations at one of the facilities of Zydus Wellness Ltd, the company said.

The company’s consolidated revenue from operations in Q4FY23 increased 29.7% to 5,010.6 crore from 3,805.6 crore, YoY.

Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 75.1% to 1,257 crore from 718 crore, while EBITDA margin expanded by 640 bps to 25% from 18.6%, YoY.

Zydus Lifesciences’s US formulations business registered revenues of 2,252.5 crore, up 58% YoY and 17% QoQ. The business accounted for 46% of consolidated revenues. In constant currency terms, the business registered revenues of $275 million. 

Growth during the quarter was driven by volume expansion in existing products and new launches, the company said.

“We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth, the US business continuing to leverage our robust product pipeline and agile supply chain and scale-up of our emerging market business," said Sharvil Patel, Managing Director, Zydus Lifesciences.

The company’s board of directors also recommended a final dividend of 6 per equity share of Re 1 each, subject to approval of the shareholders. The record date for dividend has been fixed at July 28, 2023.

At 1:50 pm, the shares of Zydus Lifesciences were trading 0.62% lower at 515.90 apiece on the BSE.

Catch Live Market Updates here

"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Updated: 18 May 2023, 02:29 PM IST
Next Story
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App